Driving Trials Forward: Study Start-Up Leadership at ICON

James Pereira's career in clinical research has been shaped by a single driving question: how do we get studies started faster? From his early days as a Clinical Research Associate to his current role as Director of Feasibility, Start-Up & Site Activation (FSA) Project Management, that focus on momentum has defined his approach to clinical trial operations. 

Today, James leads global teams responsible for accelerating study start-up across ICON's portfolio. His work spans Site identification, submissions, contracting and activation, ensuring that complex trials can open sites on time and begin enrolling patients without delay.

James began his career as a CRA, spending years working directly with investigative sites. That hands-on experience gave him a clear view of the challenges sites face: increasing protocol complexity, administrative burden, competing priorities and evolving regulatory requirements.

"Being a CRA taught me the importance of site engagement," he says. "You see firsthand how stretched sites are. They're running more studies than ever, dealing with multiple systems and managing tight timelines. If we want them to prioritize our trials, we have to make it easier for them." 

That insight became foundational when he moved into study start-up. "I was looking to transition into a leadership role. I'd done the day-to-day operations work and wanted to apply those skills at a strategic level, shaping how we select sites, set up contracts and streamline processes." 

The move felt like a natural extension of his operational background. "Everything I do now is still rooted in that site perspective. We're not just ticking boxes; we're thinking about how each step impacts the people doing the work."

One aspect of start-up work that James found particularly energizing was the speed at which milestones arrive. In clinical operations, delivery timelines often stretch across months or years. In start-up, progress is measured in weeks.

"First site open, first patient in. Those milestones come around much quicker," he explains. "You feel the momentum. There's a buzz when you hit those interim targets, and that keeps the team motivated."

For James, the most meaningful part of the work is knowing that every day saved in start-up brings treatments to patients faster. "We talk about this all the time. If we can shave weeks off the timeline, that means patients get access to potentially life-changing therapies sooner. That sense of urgency shapes everything we do."

Over the years, James has witnessed significant changes in how trials are initiated. Protocols have become more demanding, regulatory requirements vary widely by country, and contracting remains one of the toughest critical path items.

"At the same time, sites are under pressure like never before," he says. "We've had to invest heavily in how we support them through start-up."

Technology has played an important role in that effort. ICON's Firecrest portal, a centralized site activation tool, provides sites with a single access point for instructions, system links and progress tracking.

"It gives sites one place to go, a clean set of instructions and visibility into where they stand," James explains. "It declutters the environment for them, which ultimately makes things faster and smoother."

He breaks start-up down into distinct phases: site selection, submission preparation, contracting and activation. Each stage presents its own challenges. Informed consent forms require country-specific adaptations. Contracting involves coordination between legal, finance and local stakeholders. Activation requires alignment across multiple functions to ensure sites are ready to enroll.

His team works closely with sponsors, clinical operations, and local start-up teams to maintain momentum. "We're focused on identifying risks early. If too many sites are flagged as high risk, that's a signal for me to check in with the program manager and understand where I can offer support to maintain our timelines.

Proactive planning is central to that approach. "We don't wait for issues to arise. We anticipate them. We look at past performance, regional trends and acceleration opportunities to build realistic timelines and contingency plans."

As the industry continues to evolve, so does the role itself. "We're no longer just preparing documents and opening sites," James says. "We're helping shape strategy, advising on country regulations, anticipating delays and using data to inform decisions."

He sees continued investment in technology as critical to future progress. "With more systems and digital tools being used in trials, we need to ensure they integrate well and don't add to the burden. Tools like Firecrest help consolidate access and reduce confusion for sites."

James believes that success in start-up depends on strong partnerships, particularly with sponsors and clinical teams.

"The best outcomes happen when we're aligned with both," he says. "The clinical team contributes to country and site selection, reviews submission documents, supports contract discussions and conducts Site Initiation Visits. When we're locked in step, timelines improve significantly."

Sponsors rely on transparency and proactive communication. "They want to know where things stand, what risks exist and how we're addressing them. Our goal is to be predictable, fast, and forward-thinking."

This collaborative approach extends across multiple functions. "We work with feasibility, site identification, contracts, legal and regulatory teams. It's not siloed. Everyone contributes to getting studies up and running."

He recalls one particularly complex project involving a large cell and gene therapy program. "It spanned multiple regions, involved novel endpoints and had aggressive timelines. But because we brought the right people together early, from feasibility to regulatory to site contracting, we were able to navigate the challenges and deliver ahead of schedule."

That kind of cross-functional alignment requires intentional effort. "We hold regular sync-ups, leverage ICON's start-up oversight platform, Horizon, and make sure everyone has access to the same information. When we speak with one voice, it builds confidence with sponsors and sites alike."

One defining aspect of James's leadership style is ownership. He encourages his team to take responsibility for timelines, even when they involve stakeholders from other functions or the customer.

"You might be collaborating with senior leaders at the customer," he says. "But if the timeline on interim timelines slips, it impacts our commitment to activate sites on time. So you have to be clear, prepared and confident in your planning."

He sees this responsibility as a development opportunity. "When you're trusted to manage a timeline that spans multiple departments and geographies, it forces you to think strategically, communicate effectively and problem-solve under pressure."

James emphasizes building capability within the team. "There are many entry points into this space: site owner, site partner, contracts negotiator, activation specialist. Each role offers opportunities to grow."

For those starting out, he advises focusing on communication, stakeholder engagement and problem-solving. "You need to be comfortable presenting updates to senior audiences, managing expectations and finding solutions under pressure."

And above all: "Understand the site perspective. If you keep asking, 'How does this impact the site?' you'll make better decisions."

He also values process improvement. "We've worked on streamlining reporting, automating dashboards and removing white space. Even small efficiencies free up time for higher-value activities like engaging with sites or resolving bottlenecks."

For James, staying at ICON has been about being part of an organization that values innovation, collaboration and is people centric.

"We're not just delivering services. We're helping bring new treatments to patients faster. That mission shows up in how we design processes, develop tools and support our teams."

He appreciates the opportunity to lead in a dynamic area. "Start-up is challenging, but it's also incredibly rewarding. When a study opens on time and starts enrolling quickly, you know your team played a direct role in advancing patient care."

As he looks ahead, James remains focused on continuous improvement: finding smarter ways to start studies, stronger ways to collaborate and simpler ways to support sites. "Our job is to create momentum," he says. "And as long as there are patients waiting, we'll keep moving."